國藥控股(1099.HK)一度漲超11%創15個月新高 市場或押注國藥疫苗能獲緊急使用授權
格隆匯5月3日丨國藥控股(1099.HK)今日盤中一度拉昇漲11.62%報26.9港元,股價創去年1月以來新高,市值接近840億港元。外媒稱,世衞組織負責獲得藥品和衞生產品的助理總幹事上週五表示,世衞組織預計將在本週末公佈有關中國國藥及科興生物疫苗是否適合緊急使用的評估結果。另外,印尼國家醫藥管理局已於4月30日宣佈批准緊急使用中國國藥集團生產的新冠疫苗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.